OA12735A - Salts forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-YL)-allyl)-acetamide, its preparation ant its use against cancer. - Google Patents

Salts forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-YL)-allyl)-acetamide, its preparation ant its use against cancer. Download PDF

Info

Publication number: OA12735A
Authority: OA; OAPI
Prior art keywords: cancer; methyl; acetamide; pyridin; methoxy
Prior art date: 2001-12-12

Application number

OA1200400161A

Other languages

English (en)

Inventor

Daniel Tyler Richter

John Charles

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-12

Filing date

2002-11-11

Publication date

2006-06-29

2002-11-11 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-06-29 Publication of OA12735A publication Critical patent/OA12735A/en

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 68
201000011510 cancer Diseases 0.000 title claims description 50
150000003839 salts Chemical group 0.000 title abstract description 7
238000002360 preparation method Methods 0.000 title description 2
241000124008 Mammalia Species 0.000 claims abstract description 49
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims abstract description 17
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
230000003463 hyperproliferative effect Effects 0.000 claims abstract description 4
230000010261 cell growth Effects 0.000 claims description 39
230000002159 abnormal effect Effects 0.000 claims description 36
150000001875 compounds Chemical class 0.000 claims description 33
239000003112 inhibitor Substances 0.000 claims description 24
206010009944 Colon cancer Diseases 0.000 claims description 17
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 17
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 12
208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
231100000433 cytotoxic Toxicity 0.000 claims description 10
230000001472 cytotoxic effect Effects 0.000 claims description 10
208000035475 disorder Diseases 0.000 claims description 10
206010017758 gastric cancer Diseases 0.000 claims description 10
201000011549 stomach cancer Diseases 0.000 claims description 10
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
102000004190 Enzymes Human genes 0.000 claims description 8
108090000790 Enzymes Proteins 0.000 claims description 8
229940100198 alkylating agent Drugs 0.000 claims description 8
239000002168 alkylating agent Substances 0.000 claims description 8
230000003388 anti-hormonal effect Effects 0.000 claims description 8
210000003169 central nervous system Anatomy 0.000 claims description 8
206010006187 Breast cancer Diseases 0.000 claims description 7
208000026310 Breast neoplasm Diseases 0.000 claims description 7
206010033128 Ovarian cancer Diseases 0.000 claims description 7
206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
229930012538 Paclitaxel Natural products 0.000 claims description 7
208000002495 Uterine Neoplasms Diseases 0.000 claims description 7
230000002280 anti-androgenic effect Effects 0.000 claims description 7
230000000340 anti-metabolite Effects 0.000 claims description 7
239000000051 antiandrogen Substances 0.000 claims description 7
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 7
229940100197 antimetabolite Drugs 0.000 claims description 7
239000002256 antimetabolite Substances 0.000 claims description 7
208000029742 colonic neoplasm Diseases 0.000 claims description 7
239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 7
239000003102 growth factor Substances 0.000 claims description 7
230000000394 mitotic effect Effects 0.000 claims description 7
-1 méthylprednisolone Chemical compound 0.000 claims description 7
229960001592 paclitaxel Drugs 0.000 claims description 7
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
229940044693 topoisomerase inhibitor Drugs 0.000 claims description 7
206010046766 uterine cancer Diseases 0.000 claims description 7
229940123587 Cell cycle inhibitor Drugs 0.000 claims description 6
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
229960004316 cisplatin Drugs 0.000 claims description 6
229940088598 enzyme Drugs 0.000 claims description 6
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 6
229960005277 gemcitabine Drugs 0.000 claims description 6
239000000367 immunologic factor Substances 0.000 claims description 6
239000012444 intercalating antibiotic Substances 0.000 claims description 6
229960001603 tamoxifen Drugs 0.000 claims description 6
201000009030 Carcinoma Diseases 0.000 claims description 5
206010060862 Prostate cancer Diseases 0.000 claims description 5
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
229960004562 carboplatin Drugs 0.000 claims description 5
210000004072 lung Anatomy 0.000 claims description 5
206010000830 Acute leukaemia Diseases 0.000 claims description 4
206010005949 Bone cancer Diseases 0.000 claims description 4
208000018084 Bone neoplasm Diseases 0.000 claims description 4
206010006143 Brain stem glioma Diseases 0.000 claims description 4
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
208000017604 Hodgkin disease Diseases 0.000 claims description 4
208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
208000007913 Pituitary Neoplasms Diseases 0.000 claims description 4
201000005746 Pituitary adenoma Diseases 0.000 claims description 4
206010061538 Pituitary tumour benign Diseases 0.000 claims description 4
208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
208000000453 Skin Neoplasms Diseases 0.000 claims description 4
208000021712 Soft tissue sarcoma Diseases 0.000 claims description 4
206010046458 Urethral neoplasms Diseases 0.000 claims description 4
201000003761 Vaginal carcinoma Diseases 0.000 claims description 4
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 4
208000024447 adrenal gland neoplasm Diseases 0.000 claims description 4
230000000259 anti-tumor effect Effects 0.000 claims description 4
230000001684 chronic effect Effects 0.000 claims description 4
208000024207 chronic leukemia Diseases 0.000 claims description 4
229960003668 docetaxel Drugs 0.000 claims description 4
210000000750 endocrine system Anatomy 0.000 claims description 4
201000003914 endometrial carcinoma Diseases 0.000 claims description 4
201000001343 fallopian tube carcinoma Diseases 0.000 claims description 4
229960002949 fluorouracil Drugs 0.000 claims description 4
201000005202 lung cancer Diseases 0.000 claims description 4
208000020816 lung neoplasm Diseases 0.000 claims description 4
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
201000002528 pancreatic cancer Diseases 0.000 claims description 4
208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
210000002990 parathyroid gland Anatomy 0.000 claims description 4
208000021310 pituitary gland adenoma Diseases 0.000 claims description 4
230000005855 radiation Effects 0.000 claims description 4
206010038038 rectal cancer Diseases 0.000 claims description 4
201000001275 rectum cancer Diseases 0.000 claims description 4
201000000849 skin cancer Diseases 0.000 claims description 4
210000000813 small intestine Anatomy 0.000 claims description 4
210000001685 thyroid gland Anatomy 0.000 claims description 4
210000000626 ureter Anatomy 0.000 claims description 4
229960003048 vinblastine Drugs 0.000 claims description 4
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 4
208000013013 vulvar carcinoma Diseases 0.000 claims description 4
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
208000017897 Carcinoma of esophagus Diseases 0.000 claims description 3
206010007953 Central nervous system lymphoma Diseases 0.000 claims description 3
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
206010061252 Intraocular melanoma Diseases 0.000 claims description 3
208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
208000023915 Ureteral Neoplasms Diseases 0.000 claims description 3
201000005969 Uveal melanoma Diseases 0.000 claims description 3
208000030381 cutaneous melanoma Diseases 0.000 claims description 3
229960004397 cyclophosphamide Drugs 0.000 claims description 3
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
229960000975 daunorubicin Drugs 0.000 claims description 3
229960004679 doxorubicin Drugs 0.000 claims description 3
229960001904 epirubicin Drugs 0.000 claims description 3
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 3
229960000961 floxuridine Drugs 0.000 claims description 3
201000002575 ocular melanoma Diseases 0.000 claims description 3
210000004197 pelvis Anatomy 0.000 claims description 3
208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 3
201000003708 skin melanoma Diseases 0.000 claims description 3
229960004528 vincristine Drugs 0.000 claims description 3
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 7
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
190000008236 Carboplatin Chemical compound 0.000 claims 1
230000022131 cell cycle Effects 0.000 claims 1
210000003679 cervix uteri Anatomy 0.000 claims 1
239000001384 succinic acid Substances 0.000 claims 1
238000000034 method Methods 0.000 abstract description 44
201000010099 disease Diseases 0.000 abstract description 9
LLVZBTWPGQVVLW-SNAWJCMRSA-N CP-724714 Chemical class C12=CC(/C=C/CNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LLVZBTWPGQVVLW-SNAWJCMRSA-N 0.000 abstract description 7
150000002690 malonic acid derivatives Chemical class 0.000 abstract description 3
210000004027 cell Anatomy 0.000 description 30
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
230000002018 overexpression Effects 0.000 description 10
239000000243 solution Substances 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 9
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 9
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 9
239000000203 mixture Substances 0.000 description 8
208000014829 head and neck neoplasm Diseases 0.000 description 7
229940002612 prodrug Drugs 0.000 description 7
239000000651 prodrug Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
239000003937 drug carrier Substances 0.000 description 6
230000012010 growth Effects 0.000 description 6
102000001301 EGF receptor Human genes 0.000 description 5
108060006698 EGF receptor Proteins 0.000 description 5
239000002246 antineoplastic agent Substances 0.000 description 5
239000012458 free base Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
239000000872 buffer Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
238000005160 1H NMR spectroscopy Methods 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
230000030833 cell death Effects 0.000 description 3
208000019065 cervical carcinoma Diseases 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000013078 crystal Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
208000026037 malignant tumor of neck Diseases 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000011534 wash buffer Substances 0.000 description 3
VHSPZKNNNJSZSN-NSCUHMNNSA-N 6-[(e)-3-aminoprop-1-enyl]-n-[3-chloro-4-(6-methylpyridin-3-yl)oxyphenyl]quinazolin-4-amine Chemical compound C1=NC(C)=CC=C1OC(C(=C1)Cl)=CC=C1NC1=NC=NC2=CC=C(\C=C\CN)C=C12 VHSPZKNNNJSZSN-NSCUHMNNSA-N 0.000 description 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000000160 carbon, hydrogen and nitrogen elemental analysis Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
229940073584 methylene chloride Drugs 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000589969 Borreliella burgdorferi Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
201000000054 Coronary Restenosis Diseases 0.000 description 1
206010056489 Coronary artery restenosis Diseases 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
241000150452 Orthohantavirus Species 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 1
208000007135 Retinal Neovascularization Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
241000607734 Yersinia <bacteria> Species 0.000 description 1
JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
244000309466 calf Species 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000030944 contact inhibition Effects 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013058 crude material Substances 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000834 fixative Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
102000045108 human EGFR Human genes 0.000 description 1
208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
POFWRMVFWIJXHP-UHFFFAOYSA-N n-benzyl-9-(oxan-2-yl)purin-6-amine Chemical compound C=1C=CC=CC=1CNC(C=1N=C2)=NC=NC=1N2C1CCCCO1 POFWRMVFWIJXHP-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108700042226 ras Genes Proteins 0.000 description 1
102000016914 ras Proteins Human genes 0.000 description 1
108010014186 ras Proteins Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA1200400161A 2001-12-12 2002-11-11 Salts forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-YL)-allyl)-acetamide, its preparation ant its use against cancer. OA12735A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US34088501P	2001-12-12	2001-12-12

Publications (1)

Publication Number	Publication Date
OA12735A true OA12735A (en)	2006-06-29

Family

ID=23335337

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200400161A OA12735A (en)	2001-12-12	2002-11-11	Salts forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-YL)-allyl)-acetamide, its preparation ant its use against cancer.

Country Status (34)

Country	Link
US (1)	US6844349B2 (sr)
EP (1)	EP1456199A1 (sr)
JP (1)	JP4202926B2 (sr)
KR (1)	KR20040065259A (sr)
CN (1)	CN1608062A (sr)
AP (1)	AP2004003059A0 (sr)
AR (1)	AR037772A1 (sr)
AU (1)	AU2002366581A1 (sr)
BR (1)	BR0214876A (sr)
CA (1)	CA2469889A1 (sr)
DO (1)	DOP2002000544A (sr)
EA (1)	EA007412B1 (sr)
EC (1)	ECSP045148A (sr)
GE (1)	GEP20063872B (sr)
GT (1)	GT200200272A (sr)
HR (1)	HRP20040530A2 (sr)
HU (1)	HUP0402662A2 (sr)
IL (1)	IL161915A0 (sr)
IS (1)	IS7227A (sr)
MA (1)	MA27095A1 (sr)
MX (1)	MXPA04005678A (sr)
NO (1)	NO20042925L (sr)
NZ (1)	NZ532436A (sr)
OA (1)	OA12735A (sr)
PA (1)	PA8561401A1 (sr)
PE (1)	PE20030716A1 (sr)
PL (1)	PL370858A1 (sr)
RS (1)	RS46404A (sr)
TN (1)	TNSN04112A1 (sr)
TW (1)	TW200301103A (sr)
UA (1)	UA75482C2 (sr)
UY (1)	UY27572A1 (sr)
WO (1)	WO2003050108A1 (sr)
ZA (1)	ZA200402995B (sr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL161908A0 (en) *	2001-12-12	2005-11-20	Pfizer Prod Inc	Quinazoline derivatives for the treatment of abnormal cell growth
ES2400339T3 (es)	2002-07-15	2013-04-09	Symphony Evolution, Inc.	Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
EP1575592A1 (en) *	2002-12-18	2005-09-21	Pfizer Products Inc.	4-anilino quinazoline derivatives for the treatment of abnormal cell growth
EP1575936A1 (en) *	2002-12-19	2005-09-21	Pfizer Products Inc.	Complexes of e-2-methoxy-n-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
PL1628685T3 (pl)	2003-04-25	2011-05-31	Gilead Sciences Inc	Przeciwwirusowe analogi fosfonianowe
KR20080014144A (ko) *	2003-08-18	2008-02-13	화이자 프로덕츠 인크.	ｅｒｂＢ２ 항암제에 대한 투약 스케쥴
CA2744997A1 (en)	2003-09-26	2005-04-07	Exelixis, Inc.	C-met modulators and method of use
AU2004287416C1 (en) *	2003-10-27	2010-09-09	Merck Sharp & Dohme Corp.	CCR-2 antagonist salt
US20050192298A1 (en) *	2004-02-27	2005-09-01	Pfizer Inc	Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
WO2005121124A1 (en) *	2004-06-07	2005-12-22	Pfizer Products Inc.	Complexes of e-2-methoxy-n-(3-{4-[3-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and methods of preparing same
EP1778251B1 (en)	2004-07-27	2011-04-13	Gilead Sciences, Inc.	Nucleoside phosphonate conjugates as anti hiv agents
EP1896451A2 (en) *	2005-06-03	2008-03-12	Pfizer Products Incorporated	Bicyclic derivatives for the treatment of abnormal cell growth
EP1896030A1 (en) *	2005-06-03	2008-03-12	Pfizer Products Incorporated	Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
KR101424832B1 (ko) *	2006-05-16	2014-08-06	길리애드 사이언시즈, 인코포레이티드	악성 혈액 종양 치료 방법 및 악성 혈액 종양 치료용 조성물
BRPI0720169A2 (pt)	2006-12-12	2013-12-24	Takeda Pharmaceutical	Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
PT2125786E (pt) *	2006-12-21	2011-04-21	Pfizer Prod Inc	Sal succinato de 2-((4-(1-metil-4-(piridin-4-il)-1hpirazol- 3-il)fenoxi)metil)quinolina
NZ580868A (en) *	2007-04-10	2011-07-29	Myriad Pharmaceuticals Inc	Dosages and methods for the treatment of cancer
JPWO2009113560A1 (ja)	2008-03-12	2011-07-21	武田薬品工業株式会社	縮合複素環化合物
AU2009268681B2 (en) *	2008-07-08	2014-10-02	Gilead Sciences, Inc.	Salts of HIV inhibitor compounds
EA038195B1 (ru)	2009-01-16	2021-07-22	Экселиксис, Инк.	Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011153050A1 (en)	2010-06-02	2011-12-08	The Trustees Of The University Of Pennsylvania	Methods and use of compounds that bind to her2/neu receptor complex
US8993634B2 (en)	2010-06-02	2015-03-31	The Trustees Of The University Of Pennsylvania	Methods and use of compounds that bind to Her2/neu receptor complex
US8628554B2 (en)	2010-06-13	2014-01-14	Virender K. Sharma	Intragastric device for treating obesity
US10010439B2 (en)	2010-06-13	2018-07-03	Synerz Medical, Inc.	Intragastric device for treating obesity
US9526648B2 (en)	2010-06-13	2016-12-27	Synerz Medical, Inc.	Intragastric device for treating obesity
US10420665B2 (en)	2010-06-13	2019-09-24	W. L. Gore & Associates, Inc.	Intragastric device for treating obesity
US9468681B2 (en)	2013-03-01	2016-10-18	California Institute Of Technology	Targeted nanoparticles
CN111643479B (zh)	2015-07-01	2023-10-27	加州理工学院	基于阳离子粘酸聚合物的递送系统
US10779980B2 (en)	2016-04-27	2020-09-22	Synerz Medical, Inc.	Intragastric device for treating obesity
EP3661937B1 (en)	2017-08-01	2021-07-28	Gilead Sciences, Inc.	Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
WO2019241327A1 (en)	2018-06-13	2019-12-19	California Institute Of Technology	Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
WO2022009815A1 (ja) *	2020-07-06	2022-01-13	キッセイ薬品工業株式会社	オクタヒドロチエノキノリン化合物のコハク酸塩及びその結晶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6884418B1 (en) *	1989-08-04	2005-04-26	Berlex Laboratories, Inc.	Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
DE69716916T2 (de) *	1996-07-13	2003-07-03	Glaxo Group Ltd., Greenford	Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
NZ522568A (en) *	2000-06-22	2004-12-24	Pfizer Prod Inc	Substituted bicyclic derivatives for the treatment of abnormal cell growth

2002
- 2002-11-11 AP APAP/P/2004/003059A patent/AP2004003059A0/en unknown
- 2002-11-11 KR KR10-2004-7009073A patent/KR20040065259A/ko not_active Ceased
- 2002-11-11 GE GE5562A patent/GEP20063872B/en unknown
- 2002-11-11 CN CNA028248554A patent/CN1608062A/zh active Pending
- 2002-11-11 EA EA200400674A patent/EA007412B1/ru not_active IP Right Cessation
- 2002-11-11 BR BR0214876-5A patent/BR0214876A/pt not_active IP Right Cessation
- 2002-11-11 HU HU0402662A patent/HUP0402662A2/hu unknown
- 2002-11-11 NZ NZ532436A patent/NZ532436A/en unknown
- 2002-11-11 IL IL16191502A patent/IL161915A0/xx unknown
- 2002-11-11 AU AU2002366581A patent/AU2002366581A1/en not_active Abandoned
- 2002-11-11 CA CA002469889A patent/CA2469889A1/en not_active Abandoned
- 2002-11-11 PL PL02370858A patent/PL370858A1/xx not_active Application Discontinuation
- 2002-11-11 RS YU46404A patent/RS46404A/sr unknown
- 2002-11-11 OA OA1200400161A patent/OA12735A/en unknown
- 2002-11-11 WO PCT/IB2002/004708 patent/WO2003050108A1/en not_active Ceased
- 2002-11-11 MX MXPA04005678A patent/MXPA04005678A/es active IP Right Grant
- 2002-11-11 EP EP02804543A patent/EP1456199A1/en not_active Withdrawn
- 2002-11-11 UA UA20040604566A patent/UA75482C2/uk unknown
- 2002-11-11 HR HR20040530A patent/HRP20040530A2/hr not_active Application Discontinuation
- 2002-11-11 JP JP2003551132A patent/JP4202926B2/ja not_active Expired - Fee Related
- 2002-12-06 TW TW091135465A patent/TW200301103A/zh unknown
- 2002-12-09 UY UY27572A patent/UY27572A1/es not_active Application Discontinuation
- 2002-12-10 PE PE2002001185A patent/PE20030716A1/es not_active Application Discontinuation
- 2002-12-10 DO DO2002000544A patent/DOP2002000544A/es unknown
- 2002-12-10 AR ARP020104779A patent/AR037772A1/es unknown
- 2002-12-10 US US10/315,862 patent/US6844349B2/en not_active Expired - Fee Related
- 2002-12-12 PA PA20028561401A patent/PA8561401A1/es unknown
- 2002-12-12 GT GT200200272A patent/GT200200272A/es unknown
2004
- 2004-04-19 IS IS7227A patent/IS7227A/is unknown
- 2004-04-20 ZA ZA200402995A patent/ZA200402995B/en unknown
- 2004-06-08 MA MA27730A patent/MA27095A1/fr unknown
- 2004-06-11 EC EC2004005148A patent/ECSP045148A/es unknown
- 2004-06-11 TN TNP2004000112A patent/TNSN04112A1/fr unknown
- 2004-07-09 NO NO20042925A patent/NO20042925L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
GEP20063872B (en)	2006-07-10
US20030158217A1 (en)	2003-08-21
WO2003050108A8 (en)	2003-12-18
PL370858A1 (en)	2005-05-30
US6844349B2 (en)	2005-01-18
BR0214876A (pt)	2004-12-28
EA200400674A1 (ru)	2004-10-28
MA27095A1 (fr)	2004-12-20
ZA200402995B (en)	2005-04-20
PE20030716A1 (es)	2003-08-29
RS46404A (sr)	2006-10-27
TNSN04112A1 (fr)	2006-06-01
GT200200272A (es)	2003-12-12
MXPA04005678A (es)	2004-12-06
JP4202926B2 (ja)	2008-12-24
UY27572A1 (es)	2003-07-31
EP1456199A1 (en)	2004-09-15
WO2003050108A1 (en)	2003-06-19
KR20040065259A (ko)	2004-07-21
DOP2002000544A (es)	2003-06-16
HUP0402662A2 (hu)	2005-05-30
IS7227A (is)	2004-04-19
AR037772A1 (es)	2004-12-01
CN1608062A (zh)	2005-04-20
UA75482C2 (en)	2006-04-17
PA8561401A1 (es)	2005-02-04
HRP20040530A2 (en)	2004-10-31
CA2469889A1 (en)	2003-06-19
AP2004003059A0 (en)	2004-06-30
IL161915A0 (en)	2005-11-20
AU2002366581A1 (en)	2003-06-23
EA007412B1 (ru)	2006-10-27
NO20042925L (no)	2004-09-07
NZ532436A (en)	2006-01-27
ECSP045148A (es)	2004-07-23
JP2005511744A (ja)	2005-04-28
TW200301103A (en)	2003-07-01

Publication	Publication Date	Title
US6844349B2 (en)	2005-01-18	Salt forms of E-2-methoxy-N-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
KR100656310B1 (ko)	2006-12-12	Ｎ-아릴(티오)안트라닐산 아미드 유도체, 이들의 제조 및ｖｅｇｆ 수용체 티로신 키나제 억제제로서의 용도
CN108349981B (zh)	2021-03-30	新型的吡唑并[3，4－d]嘧啶化合物或其盐
CA2297326C (en)	2007-03-20	Heterocyclic compound and antitumor agent containing the same as active component
KR20200101330A (ko)	2020-08-27	Ehmt2 저해제로서의 아민-치환된 헤테로사이클릭 화합물, 이의 염, 및 이들의 합성 방법
JP7691974B2 (ja)	2025-06-12	アセチル補酵素ａシンテターゼ短鎖２（ａｃｓｓ２）の小分子阻害剤
CA2958741C (en)	2022-08-30	Quinazoline derivatives
WO2012155339A1 (zh)	2012-11-22	4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN111303123B (zh)	2021-08-31	2-(2,4,5-取代苯胺基)嘧啶化合物及其应用
EP3418277B1 (en)	2020-10-14	Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
KR20010013158A (ko)	2001-02-26	세포 증식 억제제로서의 시아노구아니딘
TWI755418B (zh)	2022-02-21	聯芳組成物和調控激酶級聯之方法
CN112341390B (zh)	2022-08-23	用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途
CN1321116C (zh)	2007-06-13	氮杂环庚烷衍生物
KR20050085835A (ko)	2005-08-29	Ｅ-2-메톡시-ｎ-（3-｛4-［3-메틸-4-（6-메틸-피리딘-3-일옥시）-페닐아미노］-퀴나졸린-6-일｝-알릴）-아세트아마이드의 착물, 및 그의 제조방법 및 용도
CN110684016A (zh)	2020-01-14	一种含氟的azd9291衍生物及其制备方法和应用
WO2013159698A1 (zh)	2013-10-31	稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用
CN107501283A (zh)	2017-12-22	取代芳甲杂基取代苯胺基缩乙二醇醚环代喹唑啉的制备及肿瘤治疗药物应用
TW202604504A (zh)	2026-02-01	含氮並環化合物、含其的藥物組合物及其應用
WO2026105155A1 (en)	2026-05-21	Tricyclic compound for breast and ovarian cancer treatment
HK1071743A (en)	2005-07-29	Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
ZA200502510B (en)	2006-02-22	Oxygenate treatment of dewaxing catalyst for greatyield of dewaxed product.
KR20030082294A (ko)	2003-10-22	신규한 아릴설포닐우레아 유도체, 그의 제조방법 및 그를함유하는 항암제 조성물
HK1257146B (en)	2021-11-26	Novel pyrazolo[3, 4-d] pyrimidine compound or salt thereof